Drug Information

PillID

Home Drugs Search Interactions Compare Blog 🌙

Benzodiazepines: Complete Patient Guide

You've probably heard some of the names: Xanax, Valium, Klonopin, Ativan. Benzodiazepines are among the most commonly prescribed medications in the world, and for good reason — they work rapidly, reliably, and powerfully for anxiety, panic, sleep, seizures, and more. Yet they are also among the most frequently misused and most dangerous medications to stop abruptly. Millions of patients take them as prescribed, and millions more struggle to stop once they've started.

Understanding what benzodiazepines actually are, how they work in the brain, what they're genuinely good for, and what the real risks are — not vague warnings but specific, mechanistic explanations — is essential for any patient prescribed these medications. Whether you've just received a prescription, have been taking a benzo for years, are trying to understand how to safely stop, or simply want to understand what the medication in your hand actually does, this guide covers it all.

What Are Benzodiazepines and How Do They Work?

Benzodiazepines are a class of psychoactive medications that work by enhancing the activity of a neurotransmitter called GABA — gamma-aminobutyric acid. GABA is the brain's primary "off switch." When a neuron receives a GABA signal, it becomes less likely to fire. GABA is the main brake on nervous system activity, keeping neurons from firing excessively and producing the calm, balanced state of a non-anxious, rested brain.

The GABA-A receptor is a protein complex on the surface of neurons that functions as a gate: when GABA binds to it, the gate opens and negatively charged chloride ions flow into the cell. This influx of negative charge — called hyperpolarization — makes the neuron harder to activate. The more chloride that flows in, the calmer the neuron.

Benzodiazepines bind to a specific site on the GABA-A receptor that is separate from where GABA binds. They don't open the gate themselves. Instead, they act as amplifiers: when GABA binds while a benzodiazepine is present, the gate opens more frequently and more easily than it would with GABA alone. The result is enhanced inhibition across the brain — reduced neuronal firing in circuits responsible for fear, stress response, wakefulness, muscle tone, and seizure propagation.

This mechanism explains all of the clinical effects of benzodiazepines at once:

• Anxiolytic (anti-anxiety): Damping down overactive fear circuits, including the amygdala
• Sedative/hypnotic: Reducing arousal by inhibiting the reticular activating system
• Anticonvulsant: Raising the seizure threshold by preventing runaway neuronal excitation
• Muscle relaxant: Reducing the excitatory drive to spinal motor neurons
• Amnestic: Impairing the formation of new memories during the period of drug effect

It also explains the fundamental difference between benzodiazepines and older sedatives like barbiturates. Barbiturates can activate GABA-A receptors directly — without GABA needing to be present — and can hold the chloride channel open indefinitely. This means there is no ceiling to their effect; enough of a barbiturate can completely shut down the brain's respiratory drive. Benzodiazepines, by contrast, can only amplify the GABA that is already there — they cannot activate the receptor on their own, and there is a physiological ceiling to how much inhibition they can produce. This is why benzodiazepines alone are rarely lethal in overdose, while barbiturate overdose was one of the leading causes of prescription drug death before benzos replaced them.

Medical Uses: What Benzodiazepines Are Actually Good At

Benzodiazepines have a well-defined set of clinical indications where they are highly effective. Understanding the distinction between what they do well and where they are often overused or misapplied is central to using them safely.

Anxiety Disorders

Benzodiazepines produce rapid, powerful relief from anxiety — this is their most widely known and most widely prescribed use. For generalized anxiety disorder (GAD), panic disorder, and social anxiety disorder, they work within 15–60 minutes of oral administration, making them uniquely useful for acute anxiety episodes. Alprazolam (Xanax) is frequently prescribed for panic attacks precisely because of this fast onset.

The critical caveat is that benzodiazepines are not first-line treatments for chronic anxiety disorders. For long-term management, SSRIs and SNRIs are the evidence-based first-line pharmacotherapy — they address the underlying neurobiology of anxiety without creating physical dependence, and they are substantially safer for long-term use. Benzodiazepines are appropriately used for short-term crisis management, as a bridge while waiting for SSRIs to become effective (which takes 4–8 weeks), or for situational anxiety such as fear of flying or dental procedures. Long-term daily benzo use for chronic anxiety is associated with tolerance, dependence, and cognitive impairment, and its long-term efficacy is not well-supported by the evidence.

Insomnia

Several benzodiazepines and related drugs (Z-drugs) are approved for short-term insomnia management. Temazepam (Restoril) and triazolam (Halcion) are the primary FDA-approved benzo options for sleep. They reduce sleep onset latency and increase total sleep time effectively.

Like their anxiolytic use, the problem with benzodiazepines for insomnia is time: they stop working as reliably after a few weeks as tolerance to sleep effects develops, and they suppress the deep slow-wave sleep and REM sleep that the brain most needs for restoration and memory consolidation. Stopping after regular use typically causes rebound insomnia — worse sleep than before treatment — which creates a powerful incentive to continue taking the drug even when it is no longer producing net benefit.

Seizure Disorders

Benzodiazepines are among the most important anticonvulsants in both emergency and chronic settings. In emergency medicine, IV or IM lorazepam (Ativan) is the first-line treatment for status epilepticus — sustained seizures that can cause permanent brain damage or death if not stopped quickly. Midazolam (Versed) is an alternative, particularly via the intranasal or IM routes when IV access is unavailable. Diazepam rectal gel (Diastat) and nasal spray (Valtoco) are prescribed for home use for patients with known recurrent acute seizure episodes.

Clonazepam (Klonopin) is unusual among benzodiazepines in that it is approved for chronic seizure prevention — specifically for absence seizures, Lennox-Gastaut syndrome, and myoclonic seizures. Its long half-life makes it suitable for regular dosing to maintain stable anticonvulsant levels. Tolerance to the anticonvulsant effects does develop with chronic use, which can limit its long-term efficacy.

Alcohol Withdrawal

Alcohol withdrawal shares the same physiological mechanism as benzodiazepine withdrawal: both involve removing a source of enhanced GABA activity from a brain that has adapted to it. Because alcohol withdrawal can cause fatal seizures and delirium tremens (DTs), it is treated with benzodiazepines — which address the underlying GABA deficiency directly. Diazepam (Valium) and chlordiazepoxide (Librium) are commonly used for alcohol withdrawal management in hospitalized patients due to their long half-lives and self-tapering effect through active metabolites. Lorazepam or oxazepam are preferred in patients with liver disease, where diazepam and chlordiazepoxide accumulate dangerously.

Alcohol withdrawal management is typically guided by the Clinical Institute Withdrawal Assessment for Alcohol (CIWA) protocol — a structured scoring system that assesses withdrawal severity and guides benzo administration. This is a clinical procedure requiring monitoring and should not be attempted at home without medical supervision.

Muscle Spasm

Diazepam (Valium) is specifically FDA-approved for relief of skeletal muscle spasm — the GABA-A receptors in the spinal cord and brainstem that regulate muscle tone respond to diazepam's effects. It is used adjunctively with rest and physical therapy for acute musculoskeletal injuries. Non-benzodiazepine muscle relaxants (cyclobenzaprine, methocarbamol, baclofen) are more commonly used long-term due to lower dependence risk.

Procedural Sedation and Preoperative Anxiety

Midazolam (Versed) is the gold standard for procedural sedation — endoscopy, bronchoscopy, minor surgery, cardioversion, and dozens of other medical procedures. Its rapid IV onset, ultra-short half-life, and reliable anterograde amnesia (patients typically remember nothing of the procedure) make it uniquely suited to this role. Patients wake quickly after the procedure ends, with minimal lingering sedation but no memory of what happened. This combination of properties — rapid onset, short duration, profound amnesia — is precisely what procedural sedation requires.

How Benzodiazepines Differ: Why Half-Life Matters More Than You Think

Many patients and even some prescribers think of benzodiazepines as basically interchangeable — "they're all the same drug." This is wrong, and the error has real clinical consequences. The single most important pharmacokinetic property distinguishing benzodiazepines is the half-life — how long the drug (and its active metabolites) remain in the body.

Consider the contrast between alprazolam (Xanax) and diazepam (Valium). Alprazolam has a short half-life of 6–12 hours with no meaningful active metabolites. Diazepam has a parent half-life of 20–70 hours, and its primary active metabolite — nordiazepam — has a half-life of 36–200 hours, meaning the total drug effect can persist for days after a single dose and can accumulate enormously with repeated dosing.

What does this mean in practice? When alprazolam wears off, it wears off quickly and relatively completely. For many patients, especially those with anxiety disorders, this abrupt decline in drug levels is experienced as a return — and sometimes an intensification — of anxiety symptoms. This "rebound anxiety" between doses is a powerful driver of dose escalation and of the perception that you need the drug more often than prescribed. The rapid offset creates a cycle: the drug provides relief, it wears off fast, anxiety spikes, you need another dose. This is one reason alprazolam is associated with higher rates of problematic use and dependence than longer-acting benzodiazepines.

Diazepam works differently. Because it is long-acting and accumulates, patients experience smoother, more sustained drug levels without sharp peaks and troughs. There is less rebound between doses. The trade-off is that with daily use, the drug builds up over days and weeks — creating a substantial drug burden that takes a very long time to clear. In a young, healthy adult, this gradual accumulation may be manageable. In an elderly patient with reduced liver metabolism, or anyone with hepatic impairment, diazepam and its active metabolites can accumulate to dangerous levels causing excessive sedation, confusion, and falls.

The clinical takeaway: short-acting benzos are more immediately reinforcing and carry higher dependence risk with chronic use. Long-acting benzos are smoother but accumulate. Matching the right pharmacokinetic profile to the patient and the clinical situation is a core prescribing skill — and the reason that all benzos are not the same.

Side Effects

Benzodiazepines produce predictable side effects that are direct extensions of their CNS depressant mechanism. Understanding these effects helps patients identify them and communicate accurately with their prescribers.

Sedation and Impaired Coordination

Sedation is both an intended effect (for sleep and procedural sedation) and the most common unwanted side effect when benzos are used for anxiety. Fatigue, drowsiness, slowed reaction time, and impaired coordination are common, particularly with higher doses or when starting a new prescription. Driving, operating heavy machinery, and activities requiring precise coordination are impaired. This impairment may diminish somewhat as tolerance to the sedating effects develops, but it does not disappear entirely with routine therapeutic use.

Anterograde Amnesia

Benzodiazepines reliably impair the formation of new memories after they are taken — a phenomenon called anterograde amnesia. Patients may behave normally, have conversations, and perform tasks during the period of drug effect but have no memory of these events afterward. This property is therapeutically valuable during procedures (patients remember nothing of an endoscopy performed under midazolam sedation) but is a problematic side effect in other contexts. Higher-potency, faster-onset benzos produce more pronounced anterograde amnesia. Triazolam (Halcion) is particularly associated with this effect. It can also combine with sleepwalking-type behaviors (eating, driving, making phone calls while asleep) that the patient has no subsequent memory of.

Falls in Elderly Patients

This is one of the most clinically significant adverse effects of benzodiazepines in practice. Sedation, impaired coordination, slowed reaction time, and muscle relaxation all contribute to fall risk — and in elderly patients, falls can be catastrophic. Hip fractures, which occur frequently in elderly patients who fall, carry significant morbidity and mortality. Multiple studies have confirmed that benzodiazepine use in older adults substantially increases hip fracture risk. This is why all benzodiazepines are on the American Geriatrics Society's Beers Criteria — the authoritative list of medications to avoid or use with extreme caution in adults 65 and older.

Respiratory Depression

Benzodiazepines alone in a healthy adult cause only modest respiratory depression that the body can typically compensate for. The danger arises with combinations: benzos plus opioids, benzos plus alcohol, or benzos plus other CNS depressants can produce synergistic respiratory depression sufficient to cause respiratory arrest. Patients with underlying pulmonary disease (COPD, sleep apnea) are at higher baseline risk and require extra caution.

Paradoxical Reactions

A minority of patients — particularly children, elderly patients, and individuals with certain neurological profiles — experience paradoxical reactions to benzodiazepines: increased anxiety, agitation, aggression, disinhibition, or excitement rather than the expected calming effect. The mechanism is not fully understood but may involve disinhibition of impulsive behaviors that are normally held in check by the brain regions being suppressed by the drug. When a paradoxical reaction occurs, the benzo should be discontinued.

Physical Dependence vs. Addiction: An Important Distinction

These two terms are used interchangeably in casual conversation but describe fundamentally different things, and the confusion causes real harm — both in the direction of patients being stigmatized for normal physiology, and in the direction of patients underestimating the clinical significance of their physical dependence.

Physical dependence is a physiological adaptation: the brain recalibrates its baseline activity in response to the sustained presence of a GABA-enhancing drug. When benzodiazepines are consistently present, the brain gradually reduces the number of GABA-A receptors, changes their composition, and modifies compensating systems to maintain overall neural balance. This adaptation happens at the cellular level whether or not the patient has any desire to misuse the drug. A patient who takes a prescribed benzodiazepine every day for six weeks because their doctor told them to will develop physical dependence. They are not addicted. They have not done anything wrong. They simply have a body that has adapted to the drug being present, which means that drug cannot be stopped without allowing the brain time to readapt.

Addiction is a behavioral and neurological syndrome characterized by compulsive drug-seeking behavior, loss of control over use, and continued use despite clearly harmful consequences. It involves changes in the brain's reward and prefrontal control circuits that are distinct from — though sometimes overlapping with — physical dependence. Not every physically dependent person is addicted. Not every addicted person is physically dependent in the medical sense.

Why does this matter? Because many patients who are appropriately prescribed benzodiazepines, used them as directed, and now need help stopping them are told — by clinicians who should know better, and by judgmental acquaintances who definitely should — that they are "addicted to Xanax" or "have an addiction problem." This framing is wrong and harmful. They have physical dependence, which is a medical issue requiring medical management, not a moral failing requiring shame. At the same time, patients should not use the distinction to minimize the reality that their body is physically dependent on the drug and requires a carefully managed medical process to discontinue safely.

Tolerance: Why Benzos Stop Working

Tolerance is the phenomenon in which the same drug dose produces progressively less effect over time. With benzodiazepines, tolerance develops at different rates for different effects — and this variability is clinically crucial.

Tolerance to the sedating and euphoric effects of benzodiazepines develops quickly — within days to a few weeks of regular use. This is why a dose that made someone drowsy or relaxed when they first took it may feel like nothing after a month of daily use. Tolerance to the sleep-inducing effects also develops relatively quickly — a hallmark of why benzos are not effective long-term treatments for chronic insomnia.

Tolerance to the anxiolytic (anti-anxiety) effects develops more slowly — typically over weeks to months — but it does develop. Patients who have taken a benzodiazepine daily for years often find that the drug no longer controls their anxiety as well as it once did, yet stopping is terrifying because of the withdrawal anxiety that follows. They may end up requiring the drug to feel baseline-normal rather than to feel genuinely better than baseline.

Tolerance to anticonvulsant effects also develops, which is why long-term benzodiazepine monotherapy for chronic seizure disorders is limited in its utility — the anticonvulsant effect diminishes over time.

The GABA-A receptor adaptations that drive tolerance are the same adaptations that produce physical dependence and make withdrawal dangerous. They are inseparable: the brain that has learned to function with GABA augmentation present will struggle — potentially catastrophically — when that augmentation is removed abruptly.

Benzodiazepine Withdrawal: One of the Few Drug Withdrawals That Can Kill

This is the most important safety information about benzodiazepines that patients need to understand.

Most drug withdrawals, while deeply unpleasant, are not medically life-threatening in otherwise healthy adults. Opioid withdrawal causes intense suffering — severe nausea, vomiting, muscle cramping, insomnia, anxiety, and profound misery — but rarely kills healthy adults directly (dehydration, aspiration, and cardiac events in vulnerable patients are exceptions). Stimulant withdrawal is exhausting and depressing but not medically dangerous. Even most psychiatric medication discontinuation syndromes are uncomfortable but not lethal.

Benzodiazepine withdrawal is different. Along with alcohol withdrawal and withdrawal from other sedative-hypnotics such as barbiturates and GHB, benzodiazepine withdrawal belongs to the small category of drug withdrawals that can cause fatal grand mal seizures. The mechanism is the same as the reason alcohol withdrawal can kill: the brain has adapted to chronic GABA enhancement, downregulating its own inhibitory capacity. When the drug is suddenly removed, excitatory neurotransmitters — particularly glutamate — are unopposed. The result is a dangerous surge of neuronal excitation that can progress from anxiety and tremors through hallucinations and extreme agitation to generalized tonic-clonic seizures and, in the worst cases, death.

The risk is greatest with:

• High-potency, short-acting benzodiazepines (especially alprazolam) — the abrupt drop in drug levels is steeper
• Long duration of daily use — more extensive receptor adaptation
• Abrupt or rapid discontinuation
• Higher doses
• Concurrent use of multiple substances that are also being stopped

Standard clinical management of benzodiazepine withdrawal involves:

1. Converting to a longer-acting benzodiazepine (typically diazepam) to smooth out the pharmacokinetic profile
2. Establishing a stable dose equivalent to the patient's current use
3. Gradually reducing the dose by no more than 5–10% every 1–2 weeks
4. Slowing the taper further when withdrawal symptoms emerge
5. Monitoring for breakthrough symptoms throughout

Many patients, particularly those with long-term high-dose use, require much slower tapers than the guidelines suggest. Individual responses vary enormously. Some patients taper successfully over a few months; others require a year or more to reduce by 50% without intolerable symptoms.

Overdose: What You Need to Know About Flumazenil and Naloxone

A benzodiazepine overdose in isolation — a healthy adult who has taken too much Xanax, for example — is rarely fatal, for the reasons described above: benzodiazepines require GABA to be present to produce their effects and cannot independently shut down respiratory drive. The primary danger is profound sedation, confusion, and the aspiration risk that comes with impaired consciousness.

The picture changes completely when benzodiazepines are combined with opioids, alcohol, or other CNS depressants. The combination is synergistic and frequently fatal. The FDA requires prominent black box warnings on both benzodiazepines and opioids about this combination, which was a primary driver of the U.S. overdose epidemic in the 2010s. Anyone prescribed both a benzodiazepine and an opioid should understand this risk and discuss alternatives with their prescriber.

Flumazenil: What It Does and Doesn't Do

Flumazenil is a benzodiazepine antagonist — it competitively blocks benzodiazepine binding at the GABA-A receptor, rapidly reversing sedation. It is available in hospital settings and works quickly. However, it is rarely used clinically for benzo overdose for two critical reasons:

• Short duration: Flumazenil has a half-life of less than 1 hour — far shorter than virtually every benzodiazepine. This means the reversal wears off while the benzo is still present, requiring repeat dosing and continuous monitoring. Patients can re-sedate after the flumazenil wears off.
• Seizure risk in dependent patients: In patients who are physically dependent on benzodiazepines, flumazenil can precipitate acute, severe withdrawal seizures — because it abruptly removes all GABA enhancement in a brain that has adapted to its presence. This can be life-threatening.

A Critical Point: Naloxone Does NOT Reverse Benzo Overdose

Naloxone (Narcan) is an opioid antagonist that reverses opioid overdose by blocking opioid receptors. It has no effect whatsoever on benzodiazepines, because benzos work through a completely different receptor system (GABA-A, not opioid receptors). If someone has overdosed on a benzodiazepine alone, administering naloxone will not help. In a combined opioid-benzo overdose, naloxone will reverse the opioid component but not the benzodiazepine component — the patient may still be significantly sedated after naloxone. This is one reason combined overdoses are so dangerous and why opioid rescue kits should always be paired with a call to 911, not used as a substitute for emergency care.

Long-Term Use Controversies

Long-term benzodiazepine use — typically defined as daily use for three months or more — has been increasingly scrutinized by regulatory agencies and researchers. Several concerns have accumulated in the literature over the past two decades.

FDA Warnings

The FDA has issued multiple safety communications about benzodiazepines over the years, including the 2016 black box warning requiring labeling about the combined opioid-benzo risk, and subsequent guidance about the risk of dependence and withdrawal even at therapeutic doses. In 2020, the FDA updated all benzodiazepine labeling to include more prominent descriptions of abuse, misuse, addiction, physical dependence, and withdrawal reactions, replacing previous language that underemphasized these risks.

Cognitive Impairment

The relationship between long-term benzodiazepine use and cognitive impairment — including questions about whether it increases the risk of dementia — is scientifically contested and has generated substantial research attention. Multiple large observational studies have found associations between long-term benzo use and cognitive decline or dementia risk. However, the direction of causality is genuinely difficult to establish: anxiety and insomnia (the conditions benzos are used to treat) are themselves associated with dementia risk. Whether benzodiazepines cause cognitive problems or are markers for the conditions that do is not definitively resolved. What is clearer is that chronic benzodiazepine use causes measurable cognitive impairment in active users — including memory impairment, slowed processing speed, and impaired visuospatial abilities — and that some but not all of this impairment reverses after the drug is stopped.

GABA Downregulation

Chronic benzodiazepine use is associated with downregulation of GABA-A receptors — the brain reduces the number of these receptors and changes their subunit composition in response to sustained artificial GABA enhancement. This is the physical substrate of both tolerance and dependence, and it may take months after stopping to fully reverse. During this period, the brain is hypersensitive to stimuli that would not normally be distressing, a phenomenon sometimes called "GABA deficiency" — though the clinical significance and reversibility of long-term receptor changes is still being studied.

Safer Alternatives to Benzodiazepines for Chronic Anxiety

The evidence base clearly supports using benzodiazepines sparingly and for short durations in most cases, with non-benzo alternatives as the foundation of long-term anxiety management. Understanding what these alternatives are — and what they can realistically offer — helps patients have productive conversations with their prescribers.

SSRIs and SNRIs — True First-Line Therapy

Selective serotonin reuptake inhibitors (SSRIs) such as sertraline (Zoloft), escitalopram (Lexapro), and paroxetine (Paxil), and serotonin-norepinephrine reuptake inhibitors (SNRIs) such as venlafaxine (Effexor) and duloxetine (Cymbalta), are the first-line pharmacotherapy for generalized anxiety disorder, panic disorder, social anxiety disorder, and PTSD — all conditions for which benzodiazepines are frequently prescribed. SSRIs/SNRIs do not cause physical dependence, do not produce tolerance to their anxiolytic effects, and are effective for long-term use. The primary drawback is delayed onset: 4–8 weeks before full therapeutic benefit, compared to benzodiazepines' 30-minute action. This is why benzos are sometimes used as a bridge during the wait for SSRI efficacy — a reasonable strategy if kept short-term.

Buspirone

Buspirone (Buspar) is a serotonin 5-HT1A partial agonist approved for generalized anxiety disorder. It causes no physical dependence, no sedation, no cognitive impairment, and no interaction with alcohol. Its limitations are that it also requires 2–4 weeks to take effect, it does not work for panic disorder or acute anxiety episodes, and patients who have previously taken benzodiazepines often find it underwhelming by comparison — a perception that partly reflects the lack of the sedating and euphoric effects they may have come to associate with anxiety relief.

Hydroxyzine

Hydroxyzine (Vistaril, Atarax) is an antihistamine with anxiolytic properties. It is not a controlled substance, causes no dependence, and can be taken as needed for acute anxiety. It is sedating, which is both a mechanism of action and a side effect. It is not appropriate for patients who need to remain fully alert but is a useful option for situational anxiety, pre-procedural anxiety, and sleep.

Beta-Blockers for Performance Anxiety

Propranolol and other beta-blockers are widely used off-label for performance anxiety — the situational anxiety associated with public speaking, musical performances, or other high-stakes events. They work by blocking the peripheral symptoms of anxiety (rapid heartbeat, trembling, sweating, voice quavering) without causing sedation or cognitive impairment. They do not address the psychological experience of anxiety directly, but removing the physical symptoms breaks the feedback loop that amplifies anxiety.

Cognitive Behavioral Therapy (CBT)

CBT is the most evidence-supported non-pharmacological treatment for anxiety disorders, and for many conditions produces results equivalent to or better than medication — with effects that persist after treatment ends, unlike medication effects that stop when the drug is discontinued. CBT teaches patients to identify and modify thought patterns and behavioral avoidance strategies that maintain anxiety. The barrier is access: therapists who specialize in CBT are not universally available and can be expensive, though digital CBT platforms have expanded access substantially.

Special Populations: Elderly Patients and Pregnancy

Elderly Patients

Older adults experience benzodiazepine effects differently from younger adults, and almost universally more intensely. Several factors converge: reduced hepatic CYP450 enzyme activity means drugs are metabolized more slowly; reduced renal clearance slows elimination of metabolites; decreased body water and increased fat percentage alter drug distribution; and age-related changes in GABA receptor sensitivity increase pharmacodynamic effects at the same blood level. The net result is that the same milligram dose of a benzodiazepine produces greater and longer-lasting sedation, cognitive impairment, and motor impairment in an 80-year-old than in a 40-year-old.

All benzodiazepines are listed in the American Geriatrics Society Beers Criteria, which is a consensus list of potentially inappropriate medications for older adults. The clinical concern is falls and hip fractures (benzodiazepine use increases hip fracture risk substantially in older adults), delirium (acute confusion that can be triggered or worsened by benzos), and worsening of cognitive function. If benzodiazepines must be used in elderly patients, shorter-acting agents without active metabolites — lorazepam, oxazepam, or temazepam — are preferred, in the lowest effective amounts for the shortest possible time. Long-acting benzos with active metabolites, particularly diazepam and chlordiazepoxide, should be avoided in elderly patients.

Pregnancy

Benzodiazepine use during pregnancy requires careful individualized risk-benefit analysis. Early studies in the 1970s and 1980s suggested a risk of cleft lip and palate with first-trimester exposure, particularly to diazepam. More recent, larger studies have produced mixed results, and the absolute risk, if present, appears to be small. The concern has not been definitively dismissed, however.

Third-trimester exposure is associated with clearer risks: neonatal withdrawal syndrome, in which the newborn — accustomed to receiving benzodiazepine via the placenta — experiences tremors, irritability, poor feeding, and respiratory depression as the drug clears after birth. "Floppy infant syndrome" — hypotonia and breathing difficulties — has also been reported with high prenatal benzo exposure near delivery. Benzodiazepines are present in breast milk, so nursing mothers should also discuss this with their prescribers.

If a pregnant patient has a condition for which benzodiazepines are the only viable treatment — such as severe, refractory seizure disorder — the risks of uncontrolled seizures during pregnancy (which are substantial) may clearly outweigh the drug risks. These decisions require individualized clinical evaluation and should involve both the prescribing physician and an obstetrician or maternal-fetal medicine specialist.

Frequently Asked Questions